Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Accord-UK Ltd (Trading style: Accord), Whiddon Valley, Barnstaple, Devon, EX32 8NS
Dipyridamole is an antithrombotic agent with antiplatelet activity.
Dipyridamole has an antithrombotic action based on its ability to modify various aspects of platelet function, such as platelet aggregation, adhesion and survival, which are factors associated with the initiation of thrombus formation.
Dipyridamole is rapidly absorbed from the gastro-intestinal tract. Peak plasma concentrations occur about 75 minutes after oral administration. Dipyridamole is highly bound to plasma proteins. A terminal half-life of 10-12 hours has been reported. It is conjugated in the liver and is mainly excreted in the faeces as glucuronides. Excretion may be delayed by reabsorption. A small amount is excreted in the urine.
Dipyridamole is detectable in breast milk, but at only approximately one seventeenth the concentration present in plasma.
Not applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
